Ness Zionda
NESS ZIONDA, Israel, June 16, 2011 -
BiondVax's Multimeric-001 Universal Influenza Vaccine
Successfully Meets Primary and Secondary Endpoints With Strong
Safety and Immunogenicity Data in 200 Participants
BiondVax Pharmaceuticals Ltd.
